The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been ...
Greenwich LifeSciences, Inc. provided an update on its Phase III clinical trial, FLAMINGO-01, which is investigating the immunotherapy GLSI-100 for preventing breast cancer recurrences.
FLAMINGO-01 Data Safety Monitoring Board (DSMB) The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification.
The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback